• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Sarcomatrix Therapeutics Corp.

Monday, June 03, 2024
CP
Cell and Gene Therapy and Genome Editing
At Sarcomatrix, we are pioneering a groundbreaking approach in the treatment of muscle diseases, offering first-in-class therapies for muscular dystrophy, cachexia, and sarcopenia. These markets, globally valued in billions, represent significant investment opportunities. Our research and clinical studies strategically pave the way to these lucrative markets, focusing on muscular dystrophies as the gateway. Our proprietary muscle screening platform has enabled us to develop a suite of genetic modifiers. These treatments are not only scientifically robust, with a well-understood mechanism of action, but also protected by strong intellectual property rights. By modulating cellular signaling pathways crucial for integrin production and activation, our therapies promote improved muscle cell adhesion, mobility, and overall health.
Sarcomatrix Therapeutics Corp.
Company Website: http://www.sarcomatrix.com
Lead Product in Development: S-969, small molecule gene modifier
Number Of Unlicensed Products (For Which You Are Seeking Partners): 12

Company HQ City

Reno

Company HQ State

Nevada

Company HQ Country

United States

CEO/Top Company Official

David R. Craig, MBA

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS